Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Placebo Administration | DRUG | Given IM in the non-dominant upper arm |
| Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 | BIOLOGICAL | Given IM in the non-dominant upper arm |
COH04S1, also known as GEO-CM04S1, is a synthetic MVA-based SARS-CoV-2 vaccine being developed for the prevention of COVID-19 infection. It is currently in Phase 2 clinical development as an investigational vaccine.
COH04S1 is being developed by GeoVax Labs, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GOVX. The vaccine is also referred to as GEO-CM04S1 in clinical trial documentation.
COH04S1 is in Phase 2 clinical development for the prevention of COVID-19 infection. It is an investigational vaccine and has not been approved by regulatory authorities. One clinical trial has been completed, which was a Phase 1/Phase 2 study.
COH04S1 has been studied in one clinical trial with the identifier NCT04639466, titled "A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection." This Phase 1/Phase 2 trial enrolled 119 participants and has been completed.
Yes, COH04S1 is the same as GEO-CM04S1. The vaccine is referred to by both names, with GEO-CM04S1 being the name used in the clinical trial title for the study NCT04639466.